GSK 232802

Drug Profile

GSK 232802

Alternative Names: 232802; GSK-232802

Latest Information Update: 19 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Vasomotor symptoms

Most Recent Events

  • 13 Jun 2009 Final efficacy and adverse events data from a phase II trial in Vasomotor symptoms presented at the 91st Annual Meeting of the Endocrine Society (ENDO-2009)
  • 15 Feb 2006 Phase-I clinical trials in Menopausal syndrome in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top